Institute for Clean Energy and Advanced Materials, Faculty of Materials and Energy, Southwest University, Chongqing, 400715, China; Chongqing Engineering Research Center for Micro-Nano Biomedical Materials and Devices, Chongqing 400715, China.
Institute for Clean Energy and Advanced Materials, Faculty of Materials and Energy, Southwest University, Chongqing, 400715, China; Chongqing Engineering Research Center for Micro-Nano Biomedical Materials and Devices, Chongqing 400715, China.
Colloids Surf B Biointerfaces. 2018 Oct 1;170:488-496. doi: 10.1016/j.colsurfb.2018.06.054. Epub 2018 Jun 25.
Nanomedicine based polymeric prodrug have showed high impact in the inhibition of tumor growth due to its high therapeutic efficiency and improved biocompatibility. Herein, we synthesized a novel star-like amphiphilic copolymer [β-CD-P(Ir-co-OEGMA), denoted as CPIO] through atom transfer radical polymerization (ATRP) to deliver the hydrophilic anticancer drug irinotecan (Ir). The polymer could form monodisperse unimolecular micelles and had excellent stability in aqueous solution. Moreover, the reduction-responsive feature of the micelles facilitated controlled release of drug, thus achieving targeted therapy and reduced toxicity to healthy cells. The in vitro cytotoxicity assays indicated that CPIO had a notable anticancer effect against HeLa and MCF-7 tumor cells. The confocal laser scanning microscopy and flow cytometry experiments revealed that CPIO micelles could be internalized into tumor cells efficiently. Furthermore, the obtained prodrug micelles produced better efficacy compared to free Ir. Moreover, the CPIO micelles showed excellent biocompatibility in vivo after intravenous injection on a mouse model. This study demonstrated that CPIO carrier could provide a rational design of a stimuli-responsive polymeric prodrug for delivery of irinotecan.
基于纳米医学的聚合物前药因其高效的治疗效果和改善的生物相容性,在抑制肿瘤生长方面显示出了巨大的影响。本文通过原子转移自由基聚合(ATRP)合成了一种新型的星型两亲性嵌段共聚物[β-CD-P(Ir-co-OEGMA),表示为 CPIO],以递送亲水性抗癌药物伊立替康(Ir)。该聚合物可以形成单分散的单分子胶束,并且在水溶液中具有出色的稳定性。此外,胶束的还原响应特性促进了药物的控制释放,从而实现了靶向治疗和降低对健康细胞的毒性。体外细胞毒性实验表明,CPIO 对 HeLa 和 MCF-7 肿瘤细胞具有显著的抗癌作用。共聚焦激光扫描显微镜和流式细胞术实验表明,CPIO 胶束可以有效地被肿瘤细胞内化。此外,与游离 Ir 相比,所得前药胶束产生了更好的疗效。此外,在小鼠模型中静脉注射后,CPIO 胶束在体内显示出良好的生物相容性。本研究表明,CPIO 载体可以为伊立替康的递送提供一种合理设计的刺激响应性聚合物前药。